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Cirrhosis induces extra-cellular fluid volume expansion, which
when the disease is advanced can be severe and poorly
responsive to therapy. Prevention and/or effective therapy
for cirrhotic edema requires understanding the stimulus that
initiates and maintains sodium retention. Despite much
study, this stimulus remains unknown. Work over the last
several years has shown that signals originating in the liver
can influence a variety of systemic functions, including extra-
cellular fluid volume control. We review work on the afferent
mechanisms triggering sodium retention in cirrhosis and
suggest that the data are most consistent with the existence
of a sensor in the hepatic circulation that contributes to
normal extra-cellular fluid volume control (that is, a ‘volume’
sensor) and that in cirrhosis, the sensor is pathologically
activated by the hepatic circulatory abnormalities caused by
the disease. Detailed analysis of the hepatic circulation in
normal conditions and cirrhosis is needed.
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Cirrhosis is a fatal disease that can only be cured by liver
transplantation. Renal and extra-renal1 sodium retention are
among its major complications. When cirrhosis is advanced,
extra-cellular fluid volume (ECFV) expansion can be severe
and therapeutically challenging, and is associated with a poor
prognosis.2–5 Prevention of ECFV expansion in patients with
cirrhosis would be desirable but, absent strict dietary sodium
control, would require understanding the mechanisms of
edema formation. However, as we detail below, although
many aspects of the pathogenesis of edema in cirrhosis are
understood, the stimulus that initiates and maintains sodium
retention remains unknown.
There is no ‘set point’ for ECFV6 and normal humans can
be in salt balance at extremely high sodium intake—for
example, 1500mmol/day.7 Hence, in the absence of renal
failure, development of systemic edema requires pathological
activation of the efferent mechanisms regulating sodium
balance. At the usual salt intake of Western societies, patients
in the early stages of cirrhosis are capable of sodium balance8
but as the disease advances, renal sodium excretion fails to
match intake and edema develops. In late stages of the
disease, sodium retention is extremely severe, a condition
that at its extremes is labeled hepatorenal syndrome, a term
with clinical and prognostic utility but without explanatory
power.
Except for edema, patients with advanced cirrhosis have a
clinical and laboratory phenotype resembling that of normal
subjects with severe ECFV depletion; that is, a ‘pre-renal’
state. Indeed, intrinsic renal function in patients with
cirrhosis, including those with hepatorenal syndrome, despite
marked renal vasoconstriction9,10 and decreased glomerular
filtration rate,11 appears normal. In fact, kidneys from
patients who expired with hepatorenal syndrome have been
successfully transplanted into patients with renal failure.11,12
In addition, as we discuss below, the severe renal sodium
retention of cirrhosis, even with hepatorenal syndrome can
be reversed by changing intra-hepatic circulatory hemody-
namics13–16 or by organ transplantation17–20, additional
evidence of normal intrinsic renal function.
How does cirrhosis provide the signal that triggers and
maintains activation of the mechanism for salt and water
conservation, mechanisms that under normal conditions
would only be activated during ECFV depletion? As discussed
below, an answer to this question has proven elusive. Recent
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work indicates, however, that signals originating in the liver
regulate multiple systemic functions, including ECFV
regulation and suggest that a ‘volume’ sensor in the hepatic
circulation is abnormally activated in cirrhosis.
PROPOSED INITIAL STIMULUS FOR EDEMA FORMATION IN
CIRRHOSIS
The stimulus that triggers salt and water retention in patients
with advanced cirrhosis is unknown and a review of the
hypotheses presented illustrates the difficulties encountered
in its pursuit.
Decreased plasma volume
Once it was recognized that patients with cirrhosis and
edema had portal hypertension, after Starling’s seminal work
on capillary exchange, it was assumed that exudation of
plasma ultra-filtrate into the peritoneum reduced plasma
volume. The lowered plasma volume activated afferent
cardiovascular sensors1 and thus enhanced the activity of
the efferent pathway of ECFV control. In this view, the
resulting salt and water retention was nonetheless ineffective
in restoring plasma volume as ultra-filtration into the
peritoneal cavity continued unabated. This hypothesis
(referred as the ‘low plasma volume’ hypothesis) was for
the most part abandoned when patients with cirrhosis and
edema were found to have increased, not decreased plasma
volume.21
Decreased ‘effective’ plasma volume
It is a tribute to the intellectual effect of the work showing
that minute changes in circulatory homeostasis have
profound effects in ECFV control22 that the low plasma
volume hypothesis was not completely abandoned, and
survived with the concept of low ‘effective’ plasma volume.
In this view, although total plasma volume in patients with
cirrhosis was increased, a large part of it was located in the
distended splachnic vascular bed, masking a decrease in
the non-portal (that is, ‘effective’) volume.23,24 Nonetheless,
the primary event triggering salt and water retention remained
ascites formation and the resulting decrease in plasma
volume in the arterial circulation. However, in studies of
patients with cirrhosis, Lieberman et al.25,26 found that
plasma volume remained unchanged after ascites removal
and postulated that renal salt and water retention preceded
ascites and edema formation. Mortimer Levy27 confirmed
this insight in elegant studies in dogs with cirrhosis; he found
that renal sodium retention and ECFV expansion preceded
the appearance of ascites. In addition, Levy measured total
plasma volume and its different ‘compartments’ and found
that total plasma volume was increased, including both the
splanchnic and non-splanchnic compartments. This land-
mark study showed that ascites and edema in cirrhosis results
from positive sodium and water balance (because of renal
sodium retention above intake), which resulted in an
expanded plasma volume and finally, in detectable edema.
The study thus confirmed what had been referred as the
‘overflow’ hypothesis of edema formation in cirrhosis and
showed that the concept of low ‘effective’ plasma volume had
no objective reality.
Increased vascular capacitance
More recently, Schrier et al.28,29 postulated that the primary
event in edema formation in cirrhosis was systemic vaso-
dilation caused by the disease, perhaps mediated by nitric
oxide.30 In this view, widely referred as to the ‘underfilling’
hypothesis of edema formation, increased capacitance of
the vascular tree initially results in relatively low plasma
volume, thereby triggering renal salt retention. As activation
of the efferent neuro-humoral pathway of volume conserva-
tion is due to a ‘relatively low’ initial plasma volume, as
ECFV increases, the activity of the pathway would be
suppressed. This would explain, for example, why plasma
renin can be ‘normal’ in patients with cirrhosis and marked
edema.8
This hypothesis rests on the assumption that systemic
vasodilation precedes systemic edema but very few studies
have analyzed this temporal relationship. Work in patients8
and rats31–33 was presented as evidence that vasodilation
precedes sodium retention. However, none of these studies
had sufficiently detailed temporal measurements to permit
firm conclusions and in some of these studies, measurements
were only obtained in a single point in time. In the most
detailed of these studies,33 decreased systemic vascular
resistance was found in cirrhotic rats that had no ascites
but already had elevated plasma aldosterone and renal
sodium retention. Hence, leaving aside the considerable
technical difficulties of measuring systemic hemodynamics
with microspheres in rodents, the major problem with this
study was that it failed to establish that systemic vasodila-
tion preceded sodium retention. In some of the other
studies, from snapshot determinations of hormonal or
hemodynamic parameters a logical sequence of events was
inferred.8 However, as we detail below, in diseases in which
ECFV control is abnormal, the secondary homeostatic
responses to primary stimuli are difficult to predict and no
conclusions can be drawn unless measurements are made
over time.
Two other observations have been presented to support
the hypothesis that systemic vasodilation is the stimulus
driving salt retention in cirrhosis. The first is a poorly
characterized clinical syndrome of low blood pressure and
decreased renal function after acute and marked decreases in
ECFV.34 However, aggressive extra-cellular fluid removal in
congestive heart failure and nephrotic syndrome, two other
edematous states with very different pathogenesis than
cirrhosis, can also be associated with worsening renal
function and/or hypotension.35–39 The second observation
is that renal salt excretion can be induced in cirrhosis with
exogenous vasoconstrictors or inhibitors of nitric oxide
synthesis.30,40–42 However, while infusions of angiotensin II,
for example, induced natriuresis, norepinephrine had little
effect although arterial pressure rose similarly.41 As we discuss
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below, the differential effect of the two vasoconstrictors
suggests alternative interpretations for these observations.
In sum, the hypotheses to explain edema formation in
cirrhosis have ranged from a true decrease in plasma volume,
to increased plasma volume (‘overflow’) because of primary
renal salt retention, to increased in vascular capacitance
(‘underfilling’). Thus, although the syndrome of cirrhosis
with edema has been known for centuries and was given its
modern name by Lae¨nnec almost two centuries ago,43 the
mechanism(s) that initiates and maintains the abnormal salt
retention remains elusive. As we discuss below, two
characteristics of multiorgan organisms with a cardiovascular
system have greatly complicated this search.
AFFERENT SENSORS AND HOMEOSTATIC RESPONSES
IN VOLUME REGULATION
Afferent sensors
That minute changes in circulatory homeostasis have
profound effects in ECFV control has been recognized since
the 1930s when it was noted that the ‘fullness’ of the blood
stream greatly determined renal responses to volume. In as
much as the blood moves along a (complex) tubular circuit,
it was inevitable that the blood volume, cardiac output, and
the size of the vascular tree (or more specifically, the arterial
tree) were initially observed as the critical variables ensuring
appropriate cardiovascular function and thus, that changes in
any of these would influence regulation of ECFV. However, as
critical as these parameters are, the function of the circulation
is not to maintain them as ‘normal’, as wide variations in
each (for example, because of changes in salt intake or
diurnal variations) are compatible with normal cardiovas-
cular function. The function of the circulation is to provide
the right amount of blood at the right pressure to the right
organ (or capillary bed) to ensure the capillary–tissue
exchange needed for cellular and organ functions. Of course,
different organs may have at the same time, vastly different
circulatory needs (for example, muscle during exercise) thus
requiring locally determined cardiovascular regulation.
The cardiovascular system can effectively manage these
many needs by the simultaneous operation of multiple
sensing mechanisms, some of which trigger efferent responses
at the local level44–46 and others which initiate efferent
systemic changes in cardiovascular function and/or ECFV
control.47,48 Of the latter, several sensors throughout the
circulation have been described.49–53 Among the best under-
stood is the baro-receptor located in the renal circulation,
capable of sensing extremely subtle changes in perfusion
pressure (in addition to neuronal input). Although the
molecular identity of the components of the efferent,
operational arm of the renal baro-receptor are known (renin,
angiotensinogen, angiotensins I and II, aldosterone, and
several enzymes), very little is known of its afferent sensor:
neither its molecular identity nor even its cellular location in
the renal circulation have been identified.54 Indeed, for the
many afferent sensors in the circulation, the exact anatomical
identity is only known for the carotid sinus of the baro-
receptor reflex. Several reasons account for this.
First, although afferent sensors responsive to changes in
arterial pressure are relatively easy to detect as pressure is
readily measurable and altered, other sensors respond to
stimuli that are harder to detect and quantify such as
‘stretch’,55 shear stress,44 pressure oscilations,56 or metabolic
changes.57–59 An additional difficulty derives from the
integration of the information transmitted by a given sensor
with information initiated by others, hence masking its
contribution to the overall efferent response. Finally, it is
important to recognize that afferent sensors can be activated
by such minute changes in cardiovascular function that the
changes can be technically challenging to measure; for
example, modest decreases in salt intake induce detectable
increases in plasma renin much sooner than changes in the
parameters used to gauge cardiovascular function (for
example, plasma volume, arterial pressure, cardiac output,
and systemic cardiovascular resistance) can be detected with
any certainty.60 These features vastly complicate experimental
detection and analysis of specific afferent sensors.
Given these complexities and the difficulty in measuring
the afferent sensors’ neuronal pathways (with technically
challenging nerve recordings), determination of the efferent
response is widely used as a surrogate for what is being
‘sensed’. For example, plasma renin increases after small
decreases in arterial pressure or plasma volume and hence, a
sudden increase in renin is frequently used as a marker for an
unmeasured and/or undetectable change in arterial pressure
or volume. This approach may be useful in well defined and
normal physiological conditions. However, snapshot deter-
minations of the levels of hormones operating the efferent
pathway of ECFV control in disease states may provide very
little information regarding the initial event of the disease
process that lead to abnormal volume regulation. This is
because initial pathological events trigger homeostatic
responses that may result in unpredictable changes of the
efferent limb of ECFV control, as discussed next.
Initial events and homeostatic responses
When a disease alters systemic cardiovascular function (for
example, acute heart failure) or the circulation of an organ
(for example, renal artery stenosis), afferent cardiovascular
sensors are pathologically activated. In response, there is an
initial activation of the efferent pathway of volume regulation
but, as the disease process advances and because of secondary
homeostatic events, the activity of the efferent pathway may
be difficult to predict. Heart failure illustrates this point. In
this disease, continuous on-time analysis during the initial
decrease in cardiac output and the subsequent homeostatic
responses was elegantly documented in the dog by Watkins
et al.61 Briefly, as illustrated in Figure 1, the study showed
that immediately after an acute decrease in cardiac output,
renin was released but as time advanced and because of
the homeostatic response to the activated renin–angiotensin
system, enhanced renal salt retention led to ECFV expansion.
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As shown, in moderate forms of congestive heart failure
(green line), the ECFV expansion ‘normalized’ plasma renin
and at the salt intake of the experiment, the dog returned
to salt balance. However, in severe heart failure (pink line),
full suppression of renin secretion never occurred and salt
and water retention continued unabated as long as salt was
ingested. These findings parallel clinical observations in
which patients with heart failure can be found to have either
normal or increased plasma renin.62,63 Needless to say, this
may be due not only to the severity of the heart failure but
also to the magnitude of the salt intake; when Cody et al.64
increased sodium intake from 10 to 100mmol/day in patients
with heart failure, plasma renin fell in some patients but not
in others.
Another well-understood disease is renal artery stenosis,
in which a decrease in renal artery perfusion pressure acutely
increases plasma renin.65 However, the homeostatic response
to an activated renin–angiotensin system results in decreased
renal sodium excretion, and if salt is ingested, the resulting
volume expansion may partially or completely inhibit renal
renin secretion.66–68 Hence, plasma renin in patients with
renovascular hypertension may be ‘normal’, high or some-
what elevated,69 and the difficulties of using plasma renin
as a diagnostic marker of hypertension due to renal artery
stenosis are well recognized.70,71 These examples illustrate
that in diseases in which systemic (heart failure) or organ-
specific (renal artery stenosis) vascular homeostasis is
compromised, the severity of the disease and the amount
of salt intake greatly influence the phenotype of the efferent
limb of volume control. This phenotype is difficult to predict
and hence, focusing on cirrhosis, snapshot determinations of
hemodynamic parameters or levels of efferent hormones once
the disease has developed are unlikely to identify the initial
stimulus that initiated sodium retention.
SYSTEMIC VASODILATION IN CIRRHOSIS IS LIKELY A
HOMEOSTATIC RESPONSE TO MARKED ECFV EXPANSION
Although the possibility that sodium retention in cirrhosis is
initiated by subtle decreases in arterial fullness cannot be
excluded with current methods, several lines of evidence
strongly suggest that rather than a primary event, the
systemic vasodilation and increased cardiac output in
cirrhosis are secondary to the marked expansion in ECFV.
First, under normal conditions, increasing ECFV by salt
intake10,72–74 or acute intravenous volume administration75
reduces systemic vascular resistance and increases cardiac
output. Systemic vasodilation is also found in diseases that
cause edema, such as right heart failure because of chronic
obstructive pulmonary disease76 and severe chronic anemia.77
In addition, although acute decreases in cardiac output are
known to induce systemic vasoconstriction, many patients
with congestive heart failure because of left ventricular failure
and marked edema were found to have much lower systemic
vascular resistance than anticipated.78 Moreover, when ECFV
is decreased in patients with edema because of heart failure,
systemic vascular resistance increases;79 that is, there is more
vasodilation during volume expansion even in primary
cardiac diseases.
Specifically focusing on cirrhosis, the temporally most
detailed study of the evolution of systemic hemodynamics
and sodium balance in cirrhosis found that volume
expansion preceded systemic vasodilation (Figure 2).80 This
result, obtained in the awake dog, an experimental animal in
which because of its large size and docility, accurate
hemodynamic measurements can be made, makes it unlikely
that systemic vasodilation is the triggering event for salt
retention in cirrhosis. In addition, in a study in which
systemic hemodynamics were measured in dogs with
secondary billiary cirrhosis in the absence of edema (by
placement of a side-to-side porto-caval shunt), both cardiac
output and systemic vascular resistance were normal.81
Further, when ECFV was acutely expanded in patients with
cirrhosis and edema82 and in dogs with chronic bile duct
ligation, there was a decrease in systemic vascular resis-
tance.83 Finally, clinical studies in patients have shown that
placement of a porto-caval shunt84 or transjugular intra-
hepatic porto-systemic shunt13,14 induced natriuresis while
Decrease in
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renin
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Figure 1 |Variable effects of a decrease in cardiac output on
plasma renin and extra-cellular fluid volume (ECFV) as a
function of time and severity of disease. An acute decrease in
cardiac output led to increased renin secretion and plasma renin
(top). Activation of the renin–angiotensin–aldosterone system
caused renal sodium retention (middle) and expansion of the
ECFV, evidenced as weight gain (bottom). When the decrease in
cardiac output was modest (green lines), as a response to the
expanded ECFV, renin secretion was inhibited and plasma renin
‘normalized.’ This allowed restoration of sodium balance at the
sodium intake of the experiment. However, when the decrease in
cardiac output was severe (pink lines), despite expanded ECFV, renin
secretion was not suppressed and renal sodium retention and edema
formation continued unabated. Adapted from Watkins et al.61
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peripheral vasodilation increased, suggesting that systemic
vasodilation is not the stimulus for salt retention.
In the aggregate, these observations suggest strongly that
the systemic vasodilation characteristic of cirrhosis is not the
primary event in the pathogenesis of its associated edema but
rather it is a homeostatic response to the marked ECFV
expansion characteristic of this disease.
ACTIVATION OF AN INTRA-HEPATIC VASCULAR SENSOR IN
CIRRHOSIS INITIATES SALT RETENTION
With normal kidney function, excess ECFV (with or without
edema) develops in diseases in which cardiovascular home-
ostasis is, at the systemic (for example, heart failure) or
organ-level (for example, renal ischemia), compromised.
Much like in these conditions, we suggest that renal salt
retention in advanced cirrhosis is due to abnormal hepatic
vascular function in which a hepatic vascular sensor involved
in volume control is pathologically activated. Several lines of
evidence support this view.
The liver has afferent sensors that regulate renal function
The hepatic circulation has baro-receptor(s) capable of
regulating renal sympathetic activity,85 and electrical stimu-
lation of peri-vascular portal nerves increases glomerular
filtration and urinary flow rates while peri-vascular stimula-
tion at the inferior vena cava is ineffective.86 The hepatorenal
baroreflex remains active in cirrhosis and thus capable of
contributing to the increased efferent renal sympathetic nerve
activity observed in the disease.87 In addition, hepatic edema
induced by infusion of glutamine into the mesenteric vein
markedly decreases renal plasma flow as well as glomerular
filtration and urinary flow rates, but hepatic or renal
denervation abolishes these changes.88 Morita et al.89 found
that an oral salt load increases urinary sodium excretion and
decreases renal nerve activity, and that these responses are
decreased and abolished, respectively, after hepatic denerva-
tion. Several investigators have also shown that portal vein
infusions can alter urinary flow and sodium excretion.
Perimutt et al.90 found that infusion of isotonic saline into
the portal vein causes greater renal sodium excretion than
when infused in the inferior vena cava. In addition, Daly
et al.91 found that intravenous infusion of hypertonic sodium
chloride into the portal vein increases urinary sodium
excretion to a greater degree than when it is infused into
the femoral vein. Similar results were obtained by Passo
et al.92 who also found that vagotomy abolishes the response
to portal vein infusion of hypertonic sodium chloride. There
also exits a hepatic sensing mechanism capable of responding
to potassium, which modulates renal potassium excretion.93
In sum, although many remaining issues need to be clarified,
there is little doubt that at least via neuronal pathways,
afferent hepatic sensors modulate renal function.
The liver has afferent sensors that regulate thirst and salt
appetite
As water and salt have become easily accessible to humans,
research on the behavioral component of the efferent
pathway of volume control has, with rare exceptions, been
all but abandoned. Yet, thirst and salt appetite are critical
components of the efferent pathway of volume regulation
and several studies indicate that they can be modulated by
signals originating in the liver. Intra-portal infusions of
hypertonic sodium chloride in experimental animals in-
creases plasma vasopressin and reduces renal water excretion,
and this response is abolished by transection of hepatic vagal
fibers.94,95 It must be noted, however, that experiments in
which no osmoreceptor could be found in the liver have also
been published.96 Vasopressin secretion is also stimulated
after partial hepatectomy.97 Moreover, infusions into the
portal vein alters drinking behavior and vagotomy abolishes
these changes.98 Interestingly, osmoreceptors and sodium
receptors in the liver activate neurons in the ventral sensory
thalamus.99 These studies suggest direct hepatic regulation of
cerebral osmo-receptors and thereby, vasopressin secretion
and thirst. In addition, Tordoff et al.100,101 found that the
liver contributed to the regulation of salt appetite and other
investigators found increased salt preference in animals with
liver disease because of bile duct obstruction.102,103
Abnormalities of the hepatic circulation can induce edema
without cirrhosis
It has long been known that patients with Budd–Chiari
syndrome (that is, hepatic vein thrombosis) develop
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Figure 2 | Temporal relationships between systemic
hemodynamics and extra-cellular fluid volume (ECFV) during
evolution of cirrhosis. During the early stages of disease,
peripheral vascular resistance (PVR) and cardiac output (CO) were
normal despite renal sodium retention and plasma volume
expansion. Detectable systemic vasodilation and increased cardiac
output occurred only after marked ECFV expansion (evidenced by
the appearance of ascites). Redrawn from Levy and Allotey.80
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increased intra-hepatic vascular pressure and edema and that
normalization of the pressure by a side-to-side porto-caval
shunt corrects the ECFV expansion.104 Similarly, in experi-
mental animals, increasing the intra-hepatic vascular pressure
by occlusion or stenosis of the hepatic veins15,105–107 induces
renal salt and water retention. Moreover, subsequent
decompression of the intra-hepatic hypertension by a side-
to-side porto-caval shunt, resolves this salt and water
retention.15,105 In marked contrast, end-to-side porto-caval
shunts are ineffective in reversing renal salt retention despite
reversal of the portal hypertension.15,105 Indeed, hepatic-
initiated salt and water retention requires abnormal intra-
hepatic circulation rather than portal hypertension; while
tightening of the hepatic veins decreases renal salt and water
excretion,15,105–107 portal hypertension because of partial
ligation of the portal vein has no effect.106–108
Cirrhosis alone is not sufficient to induce renal salt retention
In elegant experiments from Levy’s laboratory,81,109 it was
found that if a side-to-side porto-caval shunt is constructed
in dogs before induction of cirrhosis, there is no salt and
water retention. Indeed, regulation of ECFV by these
cirrhotic animals is indistinguishable from that of normals
and astonishingly, when given desoxycorticosterone acetate
(DOCA),109 they were fully capable of ‘escaping’ from the salt
retention action of this mineralocorticoid hormone, and thus
behaved normally. These elegant studies show that cirrhosis
alone does not impair ECFV regulation and indicates that
intra-hepatic vascular pressure (or a function of it) or the
composition of the hepatic blood (see below) need to be
abnormal for salt and water retention to occur.
Clinical studies in humans with advanced cirrhosis and
edema show that side-to-side porto-caval shunts that
effectively decompressed intra-hepatic hypertension leads to
resolution of their extracellular volume expansion.15,110
Similarly, partial reductions of intra-hepatic pressures with
transjugular intra-hepatic porto-systemic shunt increases
renal sodium excretion and blunts volume retention in
patients with cirrhosis.16 Indeed, reduction of intra-hepatic
vascular pressure by side-to-side porto-caval shunts111 or
transjugular intra-hepatic porto-systemic shunt112,113 may
reverse even the profound salt and water retention that
characterizes hepatorenal syndrome.
In the aggregate, these data strongly indicate that under
normal conditions input from the liver participates in ECFV
regulation. In addition, when the liver is diseased and the
hepatic circulation abnormal, the contribution of the liver to
volume regulation is deranged and triggers a systemic volume
conservation response.
NATURE OF THE INTRA-HEPATIC SENSOR INVOLVED IN
VOLUME CONTROL
In addition to sensors critical for the regulation of ECFV,
signals that originate in the liver can influence multiple
functions, including insulin secretion,114,115 pancreatic cell
proliferation,116 glucocorticoid action,117 food intake,118
energy expenditure,119 and arterial pressure and systemic
vascular resistance.117,120 The liver also senses oxygen tension
and hypoxic and/or anemic stress increases hepatic Epo gene
expression making the liver the primary source of extra-renal
erythropoietin in the adult.121,122
In none of the examples, as in the case of the hepatic
‘volume’ sensor, is the molecular identity nor the cellular
location of the sensor known. However, by analogy with
other organs and regardless of the nature of the stimulus that
may be sensed, several lines of evidence suggest that the
hepatic volume sensor(s) is located in the hepatic circulation.
As in cirrhosis, salt and water retention correlate with
increases in sinusoidal/postsinusoidal pressures,21 it may be
suggested that the afferent hepatic sensor regulating salt and
water balance is a baro-receptor inside the sinusoidal/
postsinusoidal circulation. However, it is entirely possible
that the sensor resides elsewhere in the hepatic vasculature
and rather than responding to hydrostatic pressure may
respond to other physical forces such as mechanical stretch,
shear stress, oxygen tension, hormonal, or metabolic
signaling.
Hepatic circulation
The hepatic circulation, like that of the lung, comprises a
dual blood supply, with the portal vein accounting for
approximately two-thirds of the total hepatic blood flow and
the hepatic artery providing the remaining flow with
oxygenated blood (Figure 3a). The pressures inside these
two circulations are very different but because their terminal
branches apparently drain directly into the hepatic sinusoids
(see Figure 3b), it has been suggested that a pre-capillary
sphincter allows the high pressure inside the hepatic arteriole
to fall below that of the capillaries, thereby allowing forward
flow.123 Surprisingly, however, the exact anatomical relation-
ships between the terminal branches of the portal vein, the
branches of the hepatic artery and the hepatic sinusoids are
still debated.124
Of great interest is that the hepatic artery shows significant
autoregulatory capacity;125–129 that is, the artery vasodilates
when perfusion pressure falls and constricts when it rises,
thereby maintaining a narrow hepatic arterial blood flow over
a wide range of perfusion pressures. It is intriguing that the
two other organs with an arterial circulation that show
similarly brisk autoregulation, the kidney and the brain, both
contain sensors critical for cardiovascular and volume
control: the renal baro-receptor in the kidney and the carotid
sinus in the brain. This suggests that the search for a volume
sensor in the hepatic circulation could first be focused on the
hepatic artery.
Another intriguing characteristic of the hepatic artery is
that it vasodilates when portal blood flow decreases,125,129,130
indicating the presence of a sensor in the hepatic artery,
which responds to changes in the contribution of the portal
vein to the total hepatic blood flow. It is unknown whether
this sensor responds to physical forces, metabolic, hormonal,
or oxygen signaling but because portal vein flow is highly
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sensitive to changes in circulating blood volume,131 it is
ideally suited to participate in volume regulation.
Hepatic circulation in cirrhosis
In addition to the well-characterized increase in intra-hepatic
vascular resistance and sinusoidal pressure, vascular abnorm-
alities in cirrhosis include (Figure 3c) decreased portal vein
blood flow and either increased or normal hepatic artery
blood flow,132–136 a remarkable finding nonetheless consider-
ing the loss of hepatic parenchyma that occurs in this disease.
It was also found that the lower the portal vein flow, the
higher the hepatic artery flow.135 Hence, cirrhosis is
characterized by a marked change in the composition of
the ‘mixed’ hepatic blood irrigating the liver. Of interest is
that decreased portal vein flow and maintenance of normal
hepatic artery flow occurs during hypotensive hemor-
rhage126–129 and one may assume other volume-depleted
states. It is apparent that by a yet to be discovered
mechanism, these changes could transduce a systemic volume
conservation response.
AVENUES FOR FUTURE RESEARCH
Regulation of hepatic artery tone
The vasodilatory response of the hepatic artery to decreases
in portal vein flow suggests that the hepatic afferent ‘volume’
sensor may be located in the hepatic artery and that a
detailed analysis of the factors regulating its tone would be
informative. Adenosine appears to at least partially mediate
hepatic artery dilation in response to decreased arterial
pressure.127,130 In addition, Ming et al.137,138 found that
intra-portal but not intravenous administration the adeno-
sine receptor blocker 8-phenyltheophylline or an adenosine
A1 receptor antagonist to cirrhotic rats or rats with acute
liver injury, partially normalized their blunted natriuretic
response to a sodium load. Stanley et al.139 reported similar
observations in human subjects with cirrhosis but direct
renal effects by the drugs may have been responsible for their
action. In addition, pharmacological studies must be taken
with caution as the specificity of the probes is frequently less
than ideal. However, very specific inhibitors of different
adenosine receptors are currently been developed140 and
several mice with adenosine receptor gene deletion are
available, suggesting a fruitful line of inquiry.
Other studies suggest additional research avenues. It is of
considerable interest that, similar to the pre-glomerular
arteriole, the hepatic artery is poorly responsive to the
vasoconstrictor action of angiotensin II.141 Further, like in
the renal circulation,142 vasopressin has both vasodilatory
and vasoconstrictor actions in the hepatic artery.141,143,144 A
detailed description of the vascular reactivity of the hepatic
artery and its different segments may be very illuminating.
For example, it is possible that the natriuresis induced by
several vasoconstrictors30,40–42 but not others41 may result from
their direct effects in the hepatic circulation, rather than in the
systemic vasculature.
Finally, such physiological studies need to be comple-
mented with a detailed description of the anatomical
interactions between arterioles of the hepatic artery, pre-
sinusoidal portal vein branches and hepatic sinusoids, both
under normal conditions and in the cirrhotic liver.
The signaling loop of the hepatic volume sensor
As noted above, the liver is a sensory organ, which transmits
a vast array of information to the rest of the body,
particularly to the central nervous system (see Lautt145 and
Uyama et al.146 for comprehensive reviews). Regarding ECFV
control, however, very little is known regarding the potential
volume sensor and the afferent limb that may transmit its
information. By analogy with other sensors, an acid- or
mechano-sensing ion channel is a good candidate.147,148
Interestingly, the portal vein blood pH and its concentrations
of bicarbonate and potassium can significantly vary accord-
ing to the diet’s ion content.149 Analysis of the ionic and
metabolic composition of portal vein blood in cirrhosis may
be of great interest. Little is also known regarding the hepatic
afferent pathway involved in volume regulation and its role in
cirrhotic edema. Levy and Wexler150 induced biliary cirrhosis
in dogs with or without hepatic denervation and compared
Normal liver Cirrhotic liver
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HV
PV
HA
2/3 blood
supply
1/3 blood
supply
Sinusoid
Portal
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Hepatic
arteriole PV
flow
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flow
Pressure
Figure 3 |Hepatic circulation. (a) The normal liver receives two-thirds of its blood flow from the portal vein (PV) and the remaining
one-third from the hepatic artery (HA). (b) Both the portal venules and the hepatic artrioles drain into hepatic sinusoids, but the exact
arrangement that allows forward flow of the mixed venous and arterial bloods remains unclear (adapted from WC Aird).167 (c) Cirrhosis
increases intra-hepatic vascular resistance and sinusoidal pressure. In addition, portal vein flow is markedly decreased and hepatic arterial
flow is either unchanged or increased. HV, hepatic vein.
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the evolution of their ECFV and their ability to handle a
volume load. They found that during the evolution of
cirrhosis, the animals with hepatic denervation had a
significant delay in the development of edema and were
more capable of excreting an acute volume load. However,
the anatomical complexity of the hepatic neuronal network
suggests that complete hepatic denervation is nearly im-
possible151 and that studies based on hepatic denervation
must be taken with caution. Thus, as studies in human
subjects that received orthotopic liver transplant found no
evidence for sympathetic re-innervation in the transplanted
liver up to a year after surgery,152 clinical studies on volume
regulation in these patients may be of great interest (for a
review, see Colle et al.153).
Secondary effects of volume expansion in cirrhosis
In patients with advanced cirrhosis and marked edema, salt
and water retention correlate closely with the magnitude of
the sinusoidal/postsinusoidal pressure21 and release of that
pressure by either side-to-side shunts15,110 or transjugular
intra-hepatic porto-systemic shunt13,14,16 induces natriuresis.
It is unknown whether increased intra-hepatic vascular
pressure is the signal for sodium retention in liver cirrhosis.
However, as decreased ECFV in patients with cirrhosis
decreases intra-hepaitc vascular pressure,154–156 it is likely
that marked plasma volume expansion in advanced disease
increases intra-hepatic vascular pressures. Hence, ECFV
expansion further reduces portal vein flow and thereby
increases hepatic artery flow. This may generate a closed loop
in which edema worsens the intra-hepatic circulatory
abnormalities of cirrhosis and causes greater salt avidity.
Intriguing old clinical studies found that after aggressive
diuresis, patients with cirrhosis and edema maintain normal
cardiovascular function and appear to do clinically better
when edema re-accumulation is prevented by marked salt
restriction.157–160 Excess ECFV is well known to be self-
perpetuating in congestive heart failure and edema correction
improves cardiac function.161–163 Determination if a similar
situation occurs in cirrhosis is urgently needed.
CONCLUDING REMARKS
The available evidence indicates that: (1) the liver, and likely
the hepatic circulation, has an afferent sensor that modulates
the efferent pathway of volume regulation (that is, a ‘volume’
sensor); (2) cirrhosis or restriction of hepatic vein flow raises
intra-hepatic vascular resistance, increases sinusoidal pres-
sure, decreases portal vein blood flow, and increases hepatic
artery flow (Figure 4a).104–107,132–136 Either because of
changes in the intra-hepatic physical forces or changes in
the composition of the ‘mixed’ intra-hepatic blood (for
example, oxygen tension, hormones, concentration of sub-
stances absorbed in the gut, and so on), abnormal sodium
retention is initiated and edema develops (Figure 4a); (3)
cirrhosis alone is not sufficient to induce edema. Institution
of a side-to-side porto-caval shunt prevents (if performed
before induction of cirrhosis) or corrects (if performed after
cirrhosis) renal sodium retention.81,105,107,109,110 This could
be due to decreases in sinusoidal pressure164 or maintenance
of mixing of portal venous and hepatic arterial bloods
irrigating the liver (Figure 4b); (4) in contrast, institution of
end-to-side porto-caval shunt only partially decreases the
elevated sinusoidal pressure84,164–166 and prevents mixing of
the venous and arterial hepatic blood supplies as the portal
vein blood is diverted to the inferior vena cava. Under these
PV HA
IVC
Pressure Pressure
Normal pressure
Constriction
Cirrhosis or
HV constriction
Cirrhosis and
side-to-side shunt
Cirrhosis and
end-to-side shunt
Na+ retention Na+ balance Na+ retention
Figure 4 |Hepatic vascular hemodynamics and sodium balance. (a) Cirrhosis or restriction of hepatic vein flow increases intra-hepatic
vascular resistance and sinusoidal pressure, markedly decreasing portal vein (PV) flow and increasing hepatic artery (HA) flow. Changes in the
physical forces or in the composition of the hepatic blood trigger sodium retention and edema formation. (b) Insertion of a side-to-side
porto-caval shunt decreases sinusoidal pressure and maintains mixing of portal venous and hepatic arterial bloods, irrigating the liver.
Under these conditions and despite cirrhosis, there is no sodium retention. (c) Insertion of an end-to-side porto-caval shunt only partially
decreases the elevated sinusoidal pressure and prevents mixing of the venous and arterial hepatic blood supplies as the portal vein blood is
diverted to the inferior vena cava. Under these conditions and despite normalization of portal vein pressure, sodium retention continues
unabated. HV, hepatic vein; IVC, inferior venacava.
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conditions and despite normalization of portal vein pressure,
sodium retention continues unabated (Figure 4c).15,105
In the aggregate, the data are most consistent with the
view that the ‘volume’ sensor in the hepatic circulation that
contributes to normal ECFV control is pathologically
activated in cirrhosis, much like the renal baro-receptor is
activated in renal artery stenosis. Unlike normal conditions
and because of the disease process, the resulting expanded
ECFV fails to inhibit activation of the sensor and as the
disease advances, edema worsens. We suggest that: (1)
detailed analysis of the hepatic microvascular anatomy in
control conditions and in cirrhosis; (2) elucidation of the
mechanisms regulating the tone of the hepatic artery and its
vasodilatory response to decreases in portal vein flow; and
(3) description of the changes in the composition of the
hepatic blood in cirrhosis, may identify the hepatic afferent
‘volume’ sensor or the signal that regulates it. This knowledge
would hold the promise of effective therapies for ECFV
control in cirrhosis and hepatorenal syndrome.
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